Supernus Pharmaceuticals, Inc.
SUPN· Nasdaq
SUPNSupernus Pharmaceuticals, Inc.
Filed Apr 13, 2022 · 10-K · 103 days after period end · 0001356576-22-000025
derived · Computed from the longer spans the company filed.
| Metric | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019 | Q4 2018 |
|---|---|---|---|---|
| Revenue | $159.05M | $143.56M | $100.45M | $115.93M |
| Net Income | $2.44M | $30.77M | $33.13M | $25.89M |
| EPS Diluted | — | — | $0.62 | $0.48 |
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2021 · filed Apr 13, 2022 · 103 d after period end
